Goldman Sachs analyst Corinne Johnson resumed coverage of Harmony Biosciences (HRMY) with a Neutral rating and $33 price target The firm expects the outlook for the Wakix franchise to remain the driver of the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
- Harmony Biosciences presents preclinical data for BP1.15205
- Promising Developments in Harmony Biosciences Justify Buy Rating
- Harmony Biosciences settles generic drug litigation, strengthens patent
- Harmony Biosciences Settles Patent Dispute with Lupin